These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30167396)

  • 1. Safety Profile of Levonorgestrel: A Disproportionality Analysis of Food and Drug Administration Adverse Event Reporting System (Faers) Database.
    Kurian A; Kaushik K; Subeesh V; Maheswari E; Kunnavil R
    J Reprod Infertil; 2018; 19(3):152-156. PubMed ID: 30167396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pantoprazole associated dyspepsia hypocalcemia and hyponatremia: A disproportionality analysis in FDA adverse event reporting system (FAERS) database.
    Nair HP; Kulkarni AR; Eswaran M; Subeesh V
    Arab J Gastroenterol; 2023 Feb; 24(1):1-4. PubMed ID: 36725376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
    Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety profile of levonorgestrel intrauterine system: Analysis of spontaneous reports submitted to FAERS.
    Chen L; Bao R; Tian X
    Heliyon; 2024 Sep; 10(17):e37112. PubMed ID: 39281579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system.
    Fang Z; Xu Z; Zhu W; Yu M; Ji C
    Front Pharmacol; 2023; 14():1101861. PubMed ID: 37342589
    [No Abstract]   [Full Text] [Related]  

  • 6. A real-world disproportionality analysis of Tivozanib data mining of the public version of FDA adverse event reporting system.
    Wang K; Wang M; Li W; Wang X
    Front Pharmacol; 2024; 15():1408135. PubMed ID: 38939844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of the levonorgestrel-releasing IUD: its advantages and disadvantages when compared to the copper-releasing IUDs.
    Chi IC
    Contraception; 1991 Dec; 44(6):573-88. PubMed ID: 1773615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Systematic Review and Meta-analysis of the Adverse Effects of Levonorgestrel Emergency Oral Contraceptive.
    Leelakanok N; Methaneethorn J
    Clin Drug Investig; 2020 May; 40(5):395-420. PubMed ID: 32162237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS.
    Chai S; Zhan JL; Zhao LM; Liu XD
    Ther Adv Drug Saf; 2022; 13():20420986221143266. PubMed ID: 36545565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system.
    Zhao B; Fu Y; Cui S; Chen X; Liu S; Luo L
    Front Pharmacol; 2024; 15():1333662. PubMed ID: 38533254
    [No Abstract]   [Full Text] [Related]  

  • 12. The emergency contraceptive drug, levonorgestrel: a review of post-coital oral and peri-coital vaginal administration for prevention of pregnancy.
    Sarkar NN
    J Obstet Gynaecol; 2011 Nov; 31(8):703-7. PubMed ID: 22085058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system.
    Liu M; Gu L; Zhang Y; Zhou H; Wang Y; Xu ZX
    Front Pharmacol; 2024; 15():1290975. PubMed ID: 38357304
    [No Abstract]   [Full Text] [Related]  

  • 14. New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database.
    Sessa M; Andersen M
    BioDrugs; 2021 Mar; 35(2):215-227. PubMed ID: 33609278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vemurafenib Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Disproportionality Analysis in FAERS Database.
    Neha R; Beulah E; Anusha B; Vasista S; Stephy C; Subeesh V
    Curr Rev Clin Exp Pharmacol; 2021; 16(2):168-173. PubMed ID: 32598268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
    Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
    Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
    Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
    Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System.
    Shu Y; He X; Liu Y; Wu P; Zhang Q
    Clin Epidemiol; 2022; 14():789-802. PubMed ID: 35789689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System Database for Asciminib.
    Liu Z; Wu D; Ke C; Nian Q; Chen Y; Huang Y; Chen M
    Oncology; 2024; 102(12):1084-1096. PubMed ID: 39102794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems.
    Raschi E; Girardi A; Poluzzi E; Forcesi E; Menniti-Ippolito F; Mazzanti G; De Ponti F
    Drug Saf; 2018 Aug; 41(8):745-752. PubMed ID: 29582393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.